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Abstract
Background: Diabetic macular oedema is the leading causes of blindness. Laser photocoagulation reduces the risk
of visual loss. However recurrences are common and despite laser treatment, patients with diabetic macular
oedema experienced progressive loss of vision. Stabilization of the blood retinal barrier introduces a rationale for
intravitreal triamcinolone treatment in diabetic macular oedema. This study is intended to compare the best
corrected visual acuity (BCVA) and the macular oedema index (MEI) at 3 month of primary treatment for diabetic
macular oedema between intravitreal triamcinolone acetonide (IVTA) and laser photocoagulation.
Methods: This comparative pilot study consists of 40 diabetic patients with diabetic macular oedema. The patients
were randomized into two groups using envelope technique sampling procedure. Treatment for diabetic macular
oedema was based on the printed envelope technique selected for every patient. Twenty patients were assigned
for IVTA group (one injection of IVTA) and another 20 patients for LASER group (one laser session). Main outcome
measures were mean BCVA and mean MEI at three months post treatment. The MEI was quantified using
Heidelberg Retinal Tomography II.
Results: The mean difference for BCVA at baseline [IVTA: 0.935 (0.223), LASER: 0.795 (0.315)] and at three months
post treatment [IVTA: 0.405 (0.224), LASER: 0.525 (0.289)] between IVTA and LASER group was not statistically
significant (p = 0.113 and p = 0.151 respectively). The mean difference for MEI at baseline [IVTA: 2.539 (0.914),
LASER: 2.139 (0.577)] and at three months post treatment [IVTA: 1.753 (0.614), LASER: 1.711 (0.472)] between IVTA
and LASER group was also not statistically significant (p = 0.106 and p = 0.811 respectively).
Conclusions: IVTA demonstrates good outcome comparable to laser photocoagulation as a primary treatment for
diabetic macular oedema at three months post treatment.
Trial Registration: ISRCTN05040192 (http://www.controlled-trial.com)
Background
Diabetic macular oedema (DME) is the leading causes of
blindness in an increasing number of patients with dia-
betes. Reduction of visual acuity in DME results from accu-
mulation of fluid produced from a rupture of the blood-
retinal barrier into the inner nuclear layer of the retina.
The thickened macula can be visualized on slit lamp
examination using 90 Dioptre or 78 Dioptre lens. The ret-
inal thickness can be measured or quantified by Optical
Coherent Tomography (OCT), Confocal laser scanning
using Heidelberg Retina Tomography II (HRT II) or Ret-
inal Thickness Analyzer.
Scanning laser tomography (SLT) in HRT II is a non-
invasive technique which permits the objective, topo-
graphic measurement of the fundus. SLT employs confocal
optics to attain a high resolution not only perpendicular to
× and y axis but also along z axis (the optical axis). The dis-
tribution of reflected light intensity along the optical axis
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any medium, provided the original work is properly cited.for a given pixel is described as the z-profile or confocal
intensity profile. An oedema index can be derived for each
pixel, which is sensitive to oedematous changes of the
retina. A resultant map of these oedema indices gives a
measure of the location and extent of retinal oedema. It
should be noted that the macular oedema index (MEI) is
not a measure of retinal thickness but reflects the changes
of retinal thickness based on the retinal refractive index in
the areas of oedema. The oedema index methodology has
been validated in diabetic retinopathy but not in other dis-
ease states. Change of the oedema index has been shown
to correlate with change of visual function, including loga-
rithm of the minimum angle of resolution (log MAR)
visual acuity, conventional automated static perimetry and
short-wavelength automated perimetry, in patients under-
going grid laser treatment for clinically significant macular
oedema [1].
Laser photocoagulation reduces the risk of visual loss in
60% of patients. However recurrences are common and
despite laser treatment, 26% of patients with DME experi-
enced progressive loss of vision [2]. Furthermore, 40% of
treated eyes that had retinal oedema involving the centre
of the macula at baseline still had oedema involving the
centre at 12 months, as did 25% of treated eyes at 36
months [3]. The frequency of an unsatisfactory outcome
following laser photocoagulation in some eyes with DME
has prompted interest in other treatment modalities.
Intravitreal triamcinolone acetonide (IVTA) has been
shown experimentally to reduce the breakdown of blood
retinal barrier [4]. It down regulates the production of
vascular endothelial growth factor; a known vascular per-
meability factor hence reduced the vascular permeability.
Stabilization of the blood retinal barrier introduces a
rationale for IVTA treatment in DME.
IVTA has proved to be effective in the treatment of
DME from previous study. It constitutes a newer, less
destructive treatment modality in the management of
DME. Two previous studies of primary IVTA in DME
[5,6] have shown improvement on visual acuity as well as
central macular thickness. Massin et. al. compared the
use of IVTA as an adjunctive therapy in DME eyes which
failed laser treatment where it effectively reduced the
macular thickening [7]. Jonas et. al. in 2003 reported in
their prospective, interventional, clinical case series
study, the visual acuity had significantly improved with
IVTA [8].
This study is designed to compare the best corrected
visual acuity (BCVA) and the macular oedema index
(MEI) at 3 months of primary treatment for DME
between IVTA and laser photocoagulation. Confocal
laser scanning machine, HRT II is used to quantify the
MEI pre and post treatment. To our knowledge, HRT II
has never been used as an evaluation tool in comparative
study to assess macular oedema in DME before and after
treatment.
Methods
Subjects
A comparative pilot study was conducted from June 2007
to February 2008, at Hospital Universiti Sains Malaysia,
Kelantan, Malaysia. The sample size was calculated using
‘Power and Sample Size’ software, version 2.1.31. Based on
t h er e s e a r c hd e s i g na n ds t r a t e g y ,s a m p l es i z ew a sc a l c u -
lated using ‘two proportions formula’ model with 90%
power of study. It was calculated based on improvement
of visual acuity in IVTA, 81% [8] and 25% in laser photo-
coagulation group [9]. A total 40 patients (20 per arm)
was required for this study.
Diabetic patients with newly diagnosed clinically as
DME, and age more than 18 years old were included in
this study. Patients with media opacity impairing intravi-
treal injection or laser photocoagulation procedure, DME
with proliferative diabetic retinopathy still undergoing pan
retinal photocoagulation, history of ocular surgery (eg. cat-
aract operation) or Yag procedure with the risk of further
aggravating the macular oedema, intra-ocular pressure >
25 mmHg or any established glaucoma patient, ocular or
systemic infection, known steroid allergy or responder,
history of systemic steroid within 4 months prior to ran-
domization and HbA1c more than 10% were excluded
from the study.
Sampling Procedure
Envelope technique sampling procedure was conducted.
A stack of opaque envelope was prepared with 20 envel-
opes containing a piece of paper with the word ‘IVTA’
and the remaining 20 envelopes stated ‘LASER’.T h e
envelope was drawn for each patient by a co-investigator.
This was performed once the patient had agreed to be
included in the study.
Study Procedure
All patients underwent a complete ocular and systemic
assessment once they consented for the study. The assess-
ment was performed by the primary investigator before
they were randomized into the two groups.
1. Pre-Treatment Parameters Measurements
1.1 Visual acuity
Visual acuity of both eyes was tested with the standard
retro illuminated Snellen chart. BCVA for each eye was
recorded in logarithm of the minimum angle of resolu-
tion (log MAR) notations [10] and used as a baseline.
All patients underwent subjective refraction by one
optometrist. This is important as any astigmatism of -1
Dioptre and more need to be corrected with astigmatism
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of MEI.
1.2. Fundus examination
Fundus examination was done using 78 Dioptre lens on
slit lamp bio microscopy and binocular indirect ophthal-
moscopy. DME was classified as mild, moderate and
severe based on the International Clinical Diabetic
Macular Oedema Disease Severity Scale [11].
1.3 Macular oedema index
MEI analysis has been incorporated within the HRT II as
the macular oedema mapping (MEM). The baseline
MEM was taken using the HRT II. Patients were properly
positioned in front of the HRT II system with their full
correction of astigmatism if any. The focus was then
adjusted to get a clear image of the macula formed on
the monitor. Three sets of three consecutive images were
captured each time. To ensure image quality and proper
handling, all guidelines recommended by the manufac-
turer were followed.
T h eb e s ti m a g ew a sc h o s e nb a s e do nt h eq u a l i t ya n d
smallest standard deviation. One good quality scan of each
eye was utilised in all analyses. A 0.5 mm diameter circle
was drawn using the circle draw facility of the HRT II.
The area was chosen based on the most oedematous area
and the same area was marked for the follow up photo-
graph at three months. Measurement of MEI was per-
formed by a blinded trained medical technician. After the
baseline measurement of MEI, all the patients were rando-
mized using the envelope technique. The type of treat-
ment selected would be performed the next day.
2. Treatment Procedure
2.1 Laser photocoagulation
Patients were properly positioned on a stable chair with
the chin rested on the slit lamp that was mounted with a
laser wavelength, Carl Zeiss Visulas 532S laser system.
Patients were given grid or focal laser depending on the
type of the macular oedema. Topical anaesthetic, 5% pro-
paracaine hydrochloride was instilled in the eye which
needed to be lasered. The laser settings were 50 micron
spot size, duration of 0.1 seconds and appropriate power
s t a r t e df r o m5 0m Wa n ds t e p p e du pt i l li tb u r n e dt h e
retina with light gray burn. The number of laser burn
given was based on the severity of diabetic macular
oedema (range: 20 - 200 laser burns and 500 μma w a y
f r o mt h ec e n t r eo ft h ef o v e a ) .O n l yo n es e s s i o no fl a s e r
(either focal or grid laser) was given to each patient in
LASER group. The procedure was done by Investigator A
(ophthalmologist). Patient was follow-up at 3 months post
laser and no other treatment was given during that period.
2.2 Intravitreal triamcinolone acetonide
Intravitreal injection of triamcinolone was carried out
under sterile conditions in the operation room. Patient
was admitted on a day care basis. Topical chloramphenicol
four times a day was prescribed one day prior to proce-
dure. The procedure was done under local anaesthesia
using topical 5% proparacaine hydrochloride. The selected
eye was properly cleaned and draped. An eye speculum
was then applied; flush irrigation with 5 mls 5% povidone
iodine was performed on the eye for one minute.
Triamcinolone acetonide in a single-use vial (40 mg/ml,
1 ml vial), was drawn into a 1-cc tuberculin syringe after
cleansing the top of the bottle with an alcohol wipe. A
separate 27 gauge needle was placed onto the syringe,
which was then inverted to remove air bubbles. The excess
triamcinolone was discarded till 0.1 ml (4 mg) remained in
the syringe.
T h es i t eo fi n j e c t i o nw a st h e ni d e n t i f i e d ,a t3 . 5m mi n
pseudophakic and 4 mm in phakic eye to ensure against
passage of the needle through the vitreous base. It was
given at the inferotemporal region to avoid drug deposi-
tion in front of the visual axis. Triamcinolone acetonide
of 4 mg in 0.1 mls was injected into the vitreous using a
27-gauge needle transconjunctivally. Using a single, pur-
poseful continuous manoeuvre, the 4 mg triamcinolone
acetonide was injected into the eye. The needle was
removed simultaneously with the application of cotton
tipped applicator over its entry site to prevent regurgita-
tion of the injected material. Indirect ophthalmoscopy
was performed to check for central retinal artery pulsa-
tion. The procedure was done by Investigator B (ophthal-
mologist). Topical chloramphenicol four times daily
would be continued for one week. Only one injection of
IVTA was given to each patient in IVTA group. Patient
was follow-up at 3 months post IVTA and no other treat-
ment was given during that period.
3. Post-Treatment Parameters Measurements
Patient was follow-up at 3 months post procedure. The
similar step of visual acuity and MEI assessment as pre-
treatment measurement was done. The outcome measures
were mean BCVA and mean MEI.
Statistical analysis
All the statistical method analysis was done with Statisti-
cal Package for Social Sciences (SPSS Inc) software, ver-
sion 12.0. Normality was tested using Eye-balling
(histogram pattern). Independent T-test, paired T-test
and Chi square test were used to analyze the results
where appropriate. The p value of < 0.05 is considered as
statistically significant.
Ways to minimise study error
The following steps were taken to reduce errors while
conducting the study:-
i. Patients were selected strictly based on the inclu-
sion and exclusion criteria.
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iii. IVTA and laser photocoagulation were performed
by experienced ophthalmologist who was masked to
patient’s identity. A standardised technique was used
for both procedures.
iv. The measurement of MEI was performed by one
identified and trained medical technician.
v. The primary investigator was masked to patient’s
identity and procedures when analyzing the MEI
results (pre and post intervention) of all patients.
The study was approved by the Research and Ethical
Committee, School of Medical Sciences, Universiti
Sains Malaysia [Ref: USM/PPSP
®/Ethics Com./2006
(176.3(1)].
Results
Demographic data
A total of 40 patients were enrolled into this study.
Twenty patients were assigned for IVTA group and
another 20 patients for LASER group. Mean age, duration
of Diabetes Mellitus (DM), and status of HbA1c of patients
in IVTA and LASER group is shown in Table 1. There
were 8 males (40%) and 12 females (60%) in the IVTA
group while 11 males (55%) and 9 females (45%) in the
LASER group. The severity of DME for both groups is
shown in Table 2.
Comparison of BCVA and MEI
The comparison of mean BCVA and MEI in both groups
at baseline and at three months post treatment is shown
in Table 3. The mean difference for BCVA and MEI
within the group at baseline and at three months post
treatment was statistically significant (p < 0.01). The
comparison of mean BCVA and MEI between IVTA and
LASER groups at baseline and three months post treat-
ment is shown in Table 4. The mean difference for
BCVA at baseline and at three months post treatment
between IVTA and LASER was not statistically signifi-
cant (p = 0.113 and p = 0.151 respectively). Similarly, the
mean difference for MEI at baseline and at three months
post treatment between IVTA and LASER group was
also not statistically significant (p = 0.106 and p = 0.811
respectively).
Discussion
We conducted this comparative pilot study to assess
whether there was a significant difference between
IVTA and laser photocoagulation with a single treat-
ment as primary treatment of DME at three months by
evaluating the BCVA and MEI. We used HRT II to eval-
u a t et h eD M E .W ed i dn o tp e r f o r mO C Tt oq u a n t i f y
the DME. MEM of HRT II showed very good agreement
with fundus biomicroscopy in diabetic maculopathy [1].
In this study, the duration of DM in both groups were
comparable (p = 0.972). Mean diabetic controlled as
being shown by the HbA1c results were almost the same
in each group, 8.92 (0.81) in IVTA and 9.01 (0.95) in
LASER group. The HbA1c results showed moderate con-
trolled of DM among our study samples. Our patients
had poor control of DM compared to study by Batioglu
and colleagues where the HbA1c was 4% to 6% [12].
In our study, we treat the patient either IVTA or laser
for DME and review the mean BCVA and MEI at three
months post procedure. Three months follow-up was
chosen because only a single treatment was given. The
requirement of re-treatment if needed will be given after
three months. The mean BCVA in IVTA group at three
months was 0.405 (0.224) and 0.525 (0.289) in LASER
group. The mean difference at three months was not
statistically significant (p = 0.151) which meant that
neither IVTA nor laser were superior to each other as a
primary treatment of DME at 3 months of treatment.
Our result showed a comparable outcome with study
done by Lam et al [13].
The significant improvement of BCVA in the IVTA
group (p < 0.01) in our study was similar to the studies
reported by few published data [1,14]. Our result also
Table 1 Characteristic of patients in IVTA and LASER group at baseline
Variables IVTA LASER (95% CI of mean difference) *p value
(n = 20) (n = 20)
Mean SD Mean SD
Age (year) 58.65 7.26 56.85 6.40 (-2.58, 6.18) 0.411
Duration of DM (year) 8.40 3.98 8.35 4.98 (-2.83, 2.93) 0.972
HbA1c (mmols) 8.92 0.81 9.01 0.95 (-0.65, 0.48) 0.762
DM: Diabetes Mellitus, *Independent T-test, p < 0.05 significant
Table 2 Distributions of cases according to severity of
DME
Severity of DME IVTA LASER *p value
(n = 20) (n = 20)
n%n%
Mild 6 30 9 45 0.265
Moderate 8 40 9 45
Severe 6 30 2 10
DME: Diabetic macular oedema, *Chi square test, p < 0.05 significant
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therapy at three months (p < 0.01). However a study
done by Lee et al [15] showed no significant improve-
ment of BCVA at three months after laser treatment.
The mean MEI at three months in IVTA group was
1.753 (0.614) and 1.711 (0.472) in the LASER group. The
mean difference of both groups was not statistically signifi-
cant (p = 0.811). Both modalities demonstrated compar-
able outcome of reduction of MEI at three months. There
was no published data on study using HRT II as an objec-
tive evaluation for DME post IVTA or laser treatments.
Hence we could only compare our study with study using
OCT measurement. Lam et al again reported comparable
outcome of central macular thickness of IVTA and laser
treatment at three months which was similar to our result
[13].
The significant improvement of mean MEI at three
months in the IVTA group in our study (p < 0.01) was
comparable to previous studies using OCT evaluation
[1,5,14,16-18]. We also found that the mean MEI in the
LASER group also showed significant improvement at
three months (p < 0.01). However, Lee et al [15] reported
that there was no significant improvement of central
macular thickness at 3 months after laser treatment.
They found that for DME patients, the combination
treatment (laser and IVTA) had a better therapeutic
effect than the laser alone for improving BCVA and
central macular thickness at the early follow-up time per-
iods [15].
Limitation of this present study is our number of
patients was relatively small and a bigger sample size
would give a better and reliable result. Another limita-
tion of this study was a short duration of follow up. A
longer period of follow up, at least over 12 months
w o u l dg i v em o r ev a l u ee s p e c i ally to arrive a treatment
recommendation and able to assess the side effect of
Triamcinolone. The analysis of macular oedema may be
improved by using alternative instrument like OCT to
support the HRT II findings.
Conclusions
Both IVTA and laser photocoagulation showed good
comparable outcomes in term of BCVA and MEI at
three months post treatment as primary treatment for
DME.
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